A Cochrane review pooled nine trials of regulated medical cannabis for insomnia, covering 537 adults aged 18 to 76, and found ...

Cold and flu season is making an unwelcome return. And for the 1.6million UK adults taking weight-loss injections, experts ...

Could your handwriting offer clues into how your brain is aging?

Twice-yearly lenacapavir achieved significantly higher one-year PrEP persistence than daily oral F/TDF, with 85.6% of participants receiving twice-yearly lenacapavir remaining persistent through Week ...

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the ...

Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced topline results from VOCAL, an ...

Australians could soon be able to take one of the world’s most popular weight-loss medications in tablet form, following a ...

Eli Lilly, Novo Nordisk and Pfizer went head-to-head over weight-loss drugs, with the focus shifting from injectables to oral therapies. Eli Lilly gave the first public showing of orforglipron, an ...

A major new review challenges the growing enthusiasm for medical cannabis as an insomnia treatment, finding little reliable ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, ...

A new tablet version's been approved in Australia, offering another option for people who would prefer not to (or can't) ...

Gilead will present an update from its HIV cure research program, exploring the immunogenicity and associated safety of amtabafusp alfa (GS-8588), a bispecific T-cell engager, in a Phase 1b study in ...